Tc-diphosphonate scintigraphy [1, 2] . Apparently, it seems an attractive approach to combine 18 F-fluoride PET (which has high sensitivity for the detection of osseous metastasis) with 18 F-fluorodeoxyglucose (FDG) PET (which has been established as the single most important tumor imaging modality). Combined 18 F-fluoride and 18 F-FDG imaging in a single PET/CT scan has been proposed as a method to improve cancer diagnosis, staging, and therapy monitoring, with additional advantages of reducing the number of patient visits, shortening scanning time, and avoiding radiation exposure from additional CT imaging (if PET/CT were to be performed with each of these PET tracers separately).
In a 1998 pioneer study, Hoegerle et al. introduced the combined use of 18 F-fluoride PET and 18 F-FDG PET as an advanced metabolic imaging approach for the evaluation of cancer [3] . In 2009, a pilot study was published [4, 5] by another research group, with data obtained for 18 F-FDG PET/CT alone, 18 F-fluoride PET/CT alone, and combined 18 F-FDG and 18 F-fluoride PET/CT in the same group of patients. This had attracted immediate attention and discussion [6, 7] . More recently, a full report from the same research group has been published, with data from 115 cancer cases. In their protocol, 555 MBq (15 mCi) of 18 F-FDG+185 MBq (5 mCi) of 18 F-fluoride were combined to make a cocktail tracer, while a single PET/CT image was obtained starting at 60 min after intravenous administration of the combined radiotracers [4, 5] . The authors of that study concluded that combined use of 18 F-fluoride and 18 F-FDG in a single PET/CT scan improved the diagnostic accuracy as compared with 18 F-FDG PET/CT imaging alone [4, 5] . While very appealing at first sight, there are several critical issues associated with combined 18 F-FDG and 18 F-fluoride imaging, and these will be highlighted in the following sections.
First, one of the prerequisites for (cost-effectively) performing combined 18 F-fluoride and 18 F-FDG PET/CT imaging is that there must be solid evidence that 18 F-fluoride PET/CT provides additional information (detection of more metastatic osseous lesions) to 18 F-FDG PET alone. However, available data do not support this argument. Most of our knowledge in this regard is derived experience from bone scans. Numerous publications are available comparing the diagnostic accuracy of 18 F-FDG PET/CT versus bone scintigraphy. For most tumor types, 18 F-FDG PET is superior to single photon bone scintigraphy. Liu et al. [8] and Chang et al. [9] independently reported comprehensive meta-analyses of the diagnostic properties of 18 F-FDG PET or PET/CT versus bone scintigraphy in the detection of osseous metastases in patients with lung cancer (between January 1995 and August 2010), and both found that 18 F-FDG PET or PET/CT has higher sensitivity and specificity than bone scintigraphy. Similar findings have been reported in a meta-analysis comparing the diagnostic value of 18 F-FDG PET or PET/CT versus bone scintigraphy in detecting bone metastases in patients with breast cancer [10] . The value of further dedicated bone scanning in addition to 18 F-FDG PET/CT imaging has also been questioned in patients with Hodgkin's lymphoma [11] and pediatric sarcoma [12] . In fact, a meta-analysis to compare 18 F-FDG PET, MRI, and bone scintigraphy for the diagnosis of bone metastases in all cancer types investigated (including 145 studies published from January 1995 to January 2010) revealed that 18 F-FDG PET and MRI had comparable accuracy and both were significantly more accurate than bone scintigraphy for the diagnosis of bone metastases. On either per-patient basis or per-lesion basis, the pooled sensitivity and specificity of FDG PET was significantly superior to bone scintigraphy [13] .
It is generally believed that 18 F-fluoride PET imaging, especially PET/CT, is superior to traditional bone scan. Information from CT images also improves the diagnostic specificity of a fluoride PET study. However, there are limited data in the literature evaluating its diagnostic performance. There are a few studies that examined the performance of 18 F-fluoride PET or PET/CT in identifying osseous metastases and reported excellent results [2, 14, 15] . However, we noticed that these studies had very small sample size and most studies lacked histological confirmation and direct comparison with whole-body MRI. These studies heavily depended on clinical follow-up as a critical reference standard, but this is technically difficult because increased 18 F-fluoride activity tends to be long lasting. Especially, very limited (and controversial) information is available in the literature comparing the diagnostic accuracy of 18 F-FDG PET versus 18 F-fluoride PET. Iagaru et al. reported in a pilot study that 18 F-fluoride PET/CT outperformed 18 F-FDG PET/CT in detecting osseous metastasis [16] . At the same time, findings from other investigators favor 18 F-FDG over 18 F-fluoride [17, 18] . Even with prostate cancer, the advantage of 18 F-fluoride PET over 18 F-FDG PET is questionable [19, 20] .
The underlying reason for the advantages of 18 F-FDG PET imaging has been explored. It has to be realized that osseous metastases occur (originate) in the red bone marrow rather than in the cortical bone and that 18 F-FDG PET detects bone marrow lesions [21, 22] . This partially explains the high sensitivity and also good specificity in detecting bone marrow metastases in most malignancies [8, [23] [24] [25] [26] [27] [28] [29] . The accuracy of 18 F-FDG PET in detecting and evaluating marrow metastases is as good as MRI in most cases [13, 30] . In contrast, the uptake of 99m Tc-methylene diphosphonate (MDP) or 18 F-fluoride reflects activity of bone remodeling, which serves as indirect evidence for osseous metastasis, and is often a relatively late event of reactive bone formation after bone marrow involvement. Of note, both 18 F-FDG PET and MRI (which can provide both anatomical and functional information) are able to detect and characterize bone marrow lesions; given the complementary nature of both techniques and the rise of PET/MRI systems, this combination may eventually prove to provide the highest diagnostic and prognostic accuracy in patients (suspected of) metastatic bone marrow disease. Second, although the sensitivity of 18 F-fluoride PET is high for osteoblastic lesions, its low specificity is an important concern. As pointed out in the Society of Nuclear Medicine practice guidelines, the degree of 18 F-fluoride uptake itself cannot differentiate benign from malignant lesions [31] . It has to be noted that neither 18 F-FDG nor 18 F-fluoride is specific, but when bone lesions are considered, the lack of specificity is a more problematic issue for the latter. It is well known that numerous benign bone lesions cause increased activity on 18 18 F-FDG uptake, as commonly observed in patients who are anemic, (oncological) patients with bone marrow inflammatory changes, and patients who have received chemotherapy or bone marrowstimulating agents in the recent past [34, 35] .
Third, the combined approach will limit appropriate early therapeutic response monitoring which is a major advantage of PET imaging for many tumor types. It should be emphasized that 18 F-FDG is the tracer of choice in this domain and metabolic response invariably precedes that detected by other modalities including osteoblastic response. In addition to the compromise in the diagnostic accuracy, it would be difficult to make a correct comparative estimate of the disease burden in the follow-up study or to evaluate treatment response on the combined 18 F-fluoride/ 18 F-FDG scan. While 18 F-FDG-avid metastatic bone marrow lesions may be normalized within days after successful treatment [36, 37] , foci of tracer activity on dedicated bone scanning (i.e., 99m Tc-diphosphonate scintigraphy or 18 F-fluoride PET) are often long lasting even after successful treatment [22] . It would be impossible to determine whether an abnormal osseous uptake is due to 18 F-FDG or due to 18 F-fluoride on the combined study.
In addition, a post-therapy metabolic flare phenomenon of bone marrow 18 F-FDG uptake may compromise the interpretation of 18 F-fluoride PET interpretation. Similarly, the osteoblastic flare phenomenon on bone scintigraphy and 18 F-fluoride PET, often observed in breast, prostate, and lung cancer, may confound the assessment of therapeutic response in 18 F-FDG-avid skeletal lesions. The latter is more worrisome because 18 F-fluoride uptake tends to be more intense and lasts longer compared to therapy-induced 18 F-FDG activity [38] .
Fourth, the value of standardized uptake values (SUVs), as is routinely used in current practice, is lost if combined cocktail 18 F-fluoride/ 18 F-FDG PET/CT imaging is used. While SUV measurement is still possible with the cocktail procedure (if the procedure is strictly standardized), SUV values obtained under this circumstance would be totally different from those obtained from FDG-alone PET or 18 Ffluoride-alone PET. In fact, extraosseous uptake of 18 Ffluoride in the primary malignancy has been reported [39] . At the same time, it is unknown how often increased 18 Ffluoride should be expected in soft tissue malignancies and to what extent; therefore, it is impossible to tell which portion of the SUV is contributed from FDG and which is from 18 F-fluoride. For lesions with overt abnormality, visual analysis may be sufficient [4, 5] . However, not all lesions are clear-cut. Although it should not be used as a sole criterion in determining if a lesion is benign or malignant, the SUV can be a very helpful adjunct, both for diagnostic and therapeutic response monitoring purposes. The nonavailability of the SUV negatively affects evaluation of not only osseous lesions, but all other lesions. This is especially important when comparing a lesion with blood pool or liver activity, and when comparing a lesion with a prior study.
In addition, the nonavailability of SUV would also compromise one of the strengths of 18 F-FDG imaging, i.e., defining tumor biology and thus providing prognostic information [40] . This may also apply to prostate cancer for which an 18 F-FDG PET/CT may identify significant additional lesions not detected by a bone scan [20] . Morris et al. reported that increased FDG uptake in progressive metastatic prostate cancer represented active disease sites on subsequent studies, indicating that FDG PET may help to discriminate between active versus quiescent osseous lesions in these patients [41] . In a prospective study that used a longterm follow-up, it was shown that the level of 18 F-FDG uptake in prostate cancer is an independent prognostic factor: Most (80 %) 18 F-FDG-only lesions at baseline become positive on follow-up bone scan, and SUVs are inversely correlated with prognosis [42] . Thus, it could be clinically important to know if an osseous metastasis (as well as other tumor lesions) is 18 F-FDG-avid or just 18 F-fluoride-avid, but this information cannot be provided by the combined approach.
Fifth, the methodological limitations of the published studies on this topic should be noted. Iagaru et al. [5] reported that combined 18 F-FDG and 18 F-fluoride PET whole-body imaging detected more osseous metastases in 29 patients among a total of 115 patients evaluated. However, it is unclear if tumor stage was changed or not because of these additional findings. Furthermore, the majority (62.1 %) of cases showing more osseous lesions on the combined imaging than on 18 F-FDG PET/CT were prostate cancer patients, which often are non-18 F-FDG-avid, thus limiting the patient spectrum to which these findings are applicable. Finally, since bone scintigraphy and 18 Ffluoride PET are highly nonspecific, indeterminate lesions are common. The authors of this study [5] did not have a reference standard to determine the nature of the additional lesions seen on 18 F-fluoride PET or to classify "uncertain" lesions on 18 F-FDG PET, which can be regarded as an important methodological shortcoming [43] .
Lastly, increased radiation exposure and cost of additional tracer usage have to be considered. Again, in most cases, additional bone scintigraphy/ 18 F-fluoride PET is not indicated if 18 F-FDG PET/CT is performed, while for prostate cancer, 18 F-FDG PET/CT is not indicated according to current guidelines. Besides, a recent meta-analysis comparing the cost-effectiveness between 18 F-fluoride PET or PET/CT versus planar or single photon emission computed tomography (SPECT) bone scan failed to demonstrate any cost-effective advantage for 18 F-fluoride PET or PET/CT in the assessment of metastatic bone lesions [2] .
In summary, 18 F-FDG PET/CT is a reliable imaging tool in the detection of osseous metastasis in most cases. A dedicated bone scan (including 18 F-fluoride PET/CT) may not be indicated in many cancers for the evaluation of osseous metastasis, especially at early stages. Combined use of dual tracers may compromise the imaging quality of both studies, especially for 18 F-FDG PET with respect to its ability to detect lesions in the bone marrow. We have no doubt that 18 F-fluoride PET may be valuable and provide some additional value in some selected cases and selected cancers, where 18 F-FDG is of limited value. However, the value of using the combined approach is limited in most situations. The logical notion, thus, is that for 18 F-FDG-avid tumors, there is no evidence in the literature that 18 F-fluoride PET/CT detects more osseous lesions than 18 F-FDG PET/CT, while for non- 18 F-FDG-avid tumors, 18 F-FDG PET/CT is not indicated. Both the rare occasions (when both 18 F-FDG PET and 18 F-fluoride PET are indicated) and the advantages of performing a dual tracer PET remain to be defined.
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